enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
enVVeno Medical (NASDAQ:NVNO), a company focused on deep venous disease treatment, will participate in the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. The virtual presentation will be delivered by CEO Robert Berman on Thursday, August 21, 2025, at 2:00 PM ET.
The event is part of a broader virtual conference series for biotech and medical technology companies being held from August 19-21, 2025.enVVeno Medical (NASDAQ:NVNO), azienda specializzata nel trattamento delle malattie venose profonde, parteciper脿 alla Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. La presentazione virtuale sar脿 tenuta dall'amministratore delegato Robert Berman gioved矛 21 agosto 2025 alle 14:00 ET.
L'evento fa parte di una pi霉 ampia serie di conferenze virtuali per aziende biotech e medtech in programma dal 19 al 21 agosto 2025.
enVVeno Medical (NASDAQ:NVNO), empresa centrada en el tratamiento de enfermedades venosas profundas, participar谩 en la Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. La presentaci贸n virtual ser谩 impartida por el CEO Robert Berman el jueves 21 de agosto de 2025 a las 2:00 PM ET.
El evento forma parte de una serie de conferencias virtuales m谩s amplia para compa帽铆as de biotecnolog铆a y tecnolog铆a m茅dica que se celebra del 19 al 21 de agosto de 2025.
enVVeno Medical (NASDAQ:NVNO)電� 鞁秬鞝曤Д 歆堩櫂 旃橂鞐� 欤茧牓頃橂姅 旮办梾鞙茧, Webull Financial Corporate Connect Webinar Series: Biotech/MedTech鞐� 彀胳棳頃╇媹雼�. 鞓澕鞚� 氚滍憸電� CEO 搿滊矂韸� 氩勲(Robert Berman)鞚� 2025雲� 8鞗� 21鞚� 氇╈殧鞚� 鞓ろ泟 2:00(霃欕秬鞁滉皠, ET)鞐� 歆勴枆頃╇媹雼�.
鞚� 頄夓偓電� 2025雲� 8鞗� 19鞚茧秬韯� 21鞚缄箤歆� 鞐措Μ電� 氚旍澊鞓ろ厤 氚� 鞚橂旮办垹 旮办梾 雽�靸侅潣 雿� 韥� 臧�靸� 旎嵓霟办姢 鞁滊Μ歃堨潣 鞚柬櫂鞛呺媹雼�.
enVVeno Medical (NASDAQ:NVNO), une soci茅t茅 sp茅cialis茅e dans le traitement des maladies veineuses profondes, participera 脿 la Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. La pr茅sentation virtuelle sera assur茅e par le directeur g茅n茅ral Robert Berman le jeudi 21 ao没t 2025 脿 14h00 ET.
L'茅v茅nement fait partie d'une s茅rie de conf茅rences virtuelles plus large destin茅e aux entreprises de biotechnologie et de technologies m茅dicales, qui se tiendra du 19 au 21 ao没t 2025.
enVVeno Medical (NASDAQ:NVNO), ein Unternehmen, das sich auf die Behandlung von tiefen Venenerkrankungen spezialisiert hat, wird an der Webull Financial Corporate Connect Webinar Series: Biotech/MedTech teilnehmen. Die virtuelle Pr盲sentation wird vom CEO Robert Berman gehalten am Donnerstag, den 21. August 2025, um 14:00 Uhr ET.
Die Veranstaltung ist Teil einer gr枚脽eren virtuellen Konferenzreihe f眉r Biotech- und Medizintechnikunternehmen, die vom 19. bis 21. August 2025 stattfindet.
- None.
- None.
- Live webcast on Thursday, August 21stat 2:00 PM ET
IRVINE, CA / / August 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will present at the being held virtually August 19-21, 2025.
Details for the presentation are as follows:
Date and Time: Thursday, August 21, 2025 at 2:00 PM ET
Presenter:
Registration Link:
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit .
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve庐, is a first-in-class surgical replacement venous valve being developed for the treatment of Deep Venous Insufficiency (DVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of DVI called enVVe庐. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original on ACCESS Newswire
FAQ
When is enVVeno Medical (NVNO) presenting at the Webull Financial webinar?
Who will be presenting for enVVeno Medical at the Webull Financial webinar?
What is the focus of enVVeno Medical's business?
Is the Webull Financial Corporate Connect Webinar an in-person event?
